Q1 Earnings Forecast for AGMB Issued By HC Wainwright

AgomAb Therapeutics NV (NASDAQ:AGMB) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for AgomAb Therapeutics in a report issued on Monday, June 22nd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. HC Wainwright also issued estimates for AgomAb Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.81) EPS and FY2030 earnings at ($1.80) EPS.

Several other analysts also recently commented on the company. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners began coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 price target on the stock. Morgan Stanley began coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price objective for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.75.

AgomAb Therapeutics Trading Up 0.8%

Shares of NASDAQ AGMB opened at $11.94 on Wednesday. The firm’s 50-day moving average is $11.02. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.45.

AgomAb Therapeutics News Roundup

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated and reiterated coverage with a Buy rating and a $35 price target, implying substantial upside versus the current share price. The firm also published earnings estimates for 2026-2030, signaling continued analyst attention and confidence in the company’s long-term prospects. Benzinga coverage of HC Wainwright initiation
• Positive Sentiment: AgomAb announced the design of its NOV-ERA Phase 2b study for ontunisertib in fibrostenosing Crohn’s disease, including regulatory alignment with the FDA on key study elements. The company said first patient dosing is expected in the second half of 2026, which reduces execution uncertainty and keeps the program on schedule. Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
• Neutral Sentiment: HC Wainwright’s earnings forecasts show expected losses across 2026-2030, which is typical for a clinical-stage biotech company but reinforces that AgomAb is still dependent on pipeline progress rather than near-term profitability. MarketBeat AGMB quote page

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.